Pancreatic Cancer Research

ResearcherThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research InstituteActive in the last 2 years

Laith I. Abushahin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5155-1185; OpenAlex author ID A5084923675. Sources: ClinicalTrials.gov.

Their work

Papers
11 (first author 0, last author 2)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
37
Papers, trials and grants by year

2020: 3 papers, 1 trial · 2021: 4 papers · 2022: 2 papers · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 11

  1. Simultaneous resection of pancreatic cancer and liver metastases following total neoadjuvant therapy: A case series and analysis of the National Cancer Databas… Co-author DOI 10.14701/ahbps.25-209↗
  2. Mainstreaming germline genetic testing for patients with pancreatic cancer increases uptake. Co-author DOI 10.1007/s10689-022-00300-5↗
  3. Surgical treatment of hepatic oligometastatic pancreatic ductal adenocarcinoma: An analysis of the National Cancer Database. Co-author DOI 10.1016/j.surg.2021.12.029↗
  4. First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population. Last author DOI 10.2217/fon-2021-1367↗
  5. Altered Gemcitabine and Nab-paclitaxel Scheduling Improves Therapeutic Efficacy Compared with Standard Concurrent Treatment in Preclinical Models of Pancreatic… Co-author DOI 10.1158/1078-0432.ccr-20-1422↗
  6. Real-world outcomes associated with liposomal irinotecan dose reductions in metastatic pancreatic ductal adenocarcinoma. Last author DOI 10.2217/fon-2020-0902↗
  7. Understanding the Clinical Impact of MUC5AC Expression on Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers13123059↗
  8. Development of a MicroRNA Signature Predictive of Recurrence and Survival in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers13205168↗
  9. Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgic… Co-author DOI 10.1002/cam4.3075↗
  10. Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials. Co-author DOI 10.3390/jcm9041129↗
  11. Epidermal growth factor receptor-activating mutation(E746_T751>VP) in pancreatic ductal adenocarcinoma responds to erlotinib, followed by epidermal growth fact… Co-author DOI 10.4103/jcrt.jcrt_729_18↗

Trials 1

  1. Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer Principal investigator NCT04115163↗

Closest collaborators

The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jordan M. Cloyd · 5 shared papers, 2020–2026 · strength 0.73
  2. Terence Marques Williams · 5 shared papers, 2020–2022 · strength 0.61
  3. Mary E. Dillhoff · 4 shared papers, 2020–2026 · strength 0.58
  4. Allan Tsung · 4 shared papers, 2020–2022 · strength 0.56
  5. Timothy Michael Pawlik · 3 shared papers, 2020–2026 · strength 0.52
  6. Aslam M. Ejaz · 3 shared papers, 2020–2026 · strength 0.52
  7. Anne M. Noonan · 3 shared papers, 2020–2026 · strength 0.47
  8. Ashish Manne · 2 shared papers, 2021–2026 · strength 0.45
  9. Adam R. Wolfe · 3 shared papers, 2020–2021 · strength 0.33
  10. McKenzie L. Schaefer · 1 shared paper, 2026 · strength 0.26
  11. Patrick L. Quinn · 1 shared paper, 2026 · strength 0.26
  12. Shafia Rahman · 1 shared paper, 2026 · strength 0.26
  13. Ryan N. Robb · 2 shared papers, 2021 · strength 0.23
  14. Wei Chen · 2 shared papers, 2020–2021 · strength 0.21
  15. Ashwini Kumar Esnakula · 1 shared paper, 2021 · strength 0.19
  16. Matthew J. Arango · 1 shared paper, 2022 · strength 0.17
  17. Alycia Hatashima · 1 shared paper, 2022 · strength 0.17
  18. Paul C. Cockrum · 1 shared paper, 2021 · strength 0.16
  19. Bruce Belanger · 1 shared paper, 2021 · strength 0.16
  20. George P. Kim · 1 shared paper, 2021 · strength 0.16
  21. Ahmad B. Hamad · 1 shared paper, 2022 · strength 0.15
  22. Sameek Roychowdhury · 1 shared paper, 2023 · strength 0.14
  23. Heather Hampel · 1 shared paper, 2023 · strength 0.14
  24. Mitchell L. Ramsey · 1 shared paper, 2023 · strength 0.14
  25. Ahmad Hegazi · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.